Showing results (1361-1370 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 17, 2025
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicityJae Hyun Kim, Ja-Young Han, Jae-Hee Kwon, et al.
Investigational New Drugs|February 15, 2025
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cellsLeilane Sales Oliveira, João Marcos Oliveira-Silva, Hebreia Oliveira Almeida-Souza, et al.
Investigational New Drugs|February 24, 2025
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitisYong Pan, Wei Li, Zhaoquan Wu, et al.
Investigational New Drugs|August 3, 2024
A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumorsMohammad H Ghalib, Mariano Provencio Pulla, Maria J De Miguel Luken, et al.
Investigational New Drugs|August 12, 2024
Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting systemChunyong Xia, Zhijing Liu, Jie Liu, et al.
Investigational New Drugs|August 13, 2024
Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapiesHelin Li, Wenjing Zhang, Qiu Meng, et al.
Investigational New Drugs|August 21, 2024
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohortYusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, et al.
Investigational New Drugs|June 27, 2024
A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumorJingqiao Wu, Zhaoyu Lan, Xin Li, et al.
Investigational New Drugs|April 6, 2006
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxaneJ A Ajani, H Safran, C Bokemeyer, et al.
Investigational New Drugs|February 28, 2006
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trialToshiyuki Sawa, Takashi Yana, Minoru Takada, et al.
Pageof 372